Compare Ecolab Inc. (ECL) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ecolab Inc. vs Spyre Therapeutics Inc. Common Stock — how do they compare? Ecolab Inc. trades at $288.87 (market cap $80.08B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Ecolab Inc. is far larger — about 10.6× Spyre Therapeutics Inc. Common Stock's market cap, and Ecolab Inc. pays a 1.02% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ecolab Inc. for 91 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| ECL | SYRE | |
|---|---|---|
Market Cap | $80.08B | $7.52B |
Volume | 1,150,296 | 1,441,031 |
Sector | Basic Materials | Health |
52-Week High | $308.35 | $108.92 |
52-Week Low | $245.73 | $22.18 |
Typical Hold Time | 91 Days | 0 Days |
Enterprise Value | $88.86B | $6.52B |
Dividend Yield | 1.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ECL trades at $287.79, up 1.23% today, with a bullish technical signal and strong analyst support. The stock shows robust fundamentals, including a 12.57% net income margin and 21.85% ROE, with revenue growth from $16.08B in 2025 to a projected $16.8B in 2026. Recent news highlights its dividend consistency and High-Tech segment growth, while institutional buying and insider purchases reflect confidence.
Outlook is positive with a consensus price target of $326.38, implying 13% upside, driven by earnings beats and digital expansion. Risks include elevated P/E of 38.34 and rising debt from the CoolIT acquisition. The stock remains a buy for growth-oriented investors, balancing steady cash flows with execution risks in a competitive market.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Ecolab Inc.
Ecolab produces and markets cleaning and sanitation products for the hospitality, healthcare, and industrial markets. The firm is the global market share leader in this category with a wide array of products and services, including dish and laundry washing systems, pest control, and infection control products. The company has a strong hold on the U.S. market and is looking to increase its profitability abroad. Additionally, Ecolab serves customers in water, manufacturing, and life sciences end markets, selling customized solutions.
Read more on ECL →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
